Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version ...
Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
The Tandem Mobi app will be downloadable from the Google Play Store on compatible smartphones, including Google Pixel and ...
Investing.com - Stifel resumed coverage of DexCom (NASDAQ:DXCM) with a Buy rating and set a price target of $85.00, according to a research note published Monday. The company, currently trading at $68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback